The value of NGS-based multi-gene testing for differentiation of benign from malignant and risk stratification of thyroid nodules.

33 (9.19%) samples were classified as non-diagnostic (Bethesda I), 149 (41.50%) as benign (Bethesda II), 47 (13.10%) as atypia of indeterminate significance/follicular lesion of indeterminate significance (AUS/FLUS, Bethesda III), 7 (1.95%) as follicular neoplasm/suspicious for follicular neoplasm (FN/SFN, Bethesda IV), 17 (4.74%) as suspicious for malignancy (SUSP, Bethesda V), and 123 (29.53%) as malignant (Bethesda VI).

also in 137 other papers